22 February 2024 - Curium announced today that the marketing authorisation application for Pylclari (piflufolastat (18F)) submitted by exclusive Swiss distributor b.e.imaging AG on 31 January 2024 to Swissmedic has been accepted for evaluation.

Pylclari is indicated for the detection of prostate-specific membrane antigen positive lesions with positron emission tomography in adults with prostate cancer in the following clinical settings:

• Primary staging of patients with high-risk prostate cancer prior to initial curative therapy
• To localise recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen levels after primary treatment with curative intent

Read Curium press release